We are live on ! Find out more
TARO

Taro Pharmaceutical Industries Ltd.

Delisted

TARO was delisted on the 21st of June, 2024.

94 hedge funds and large institutions have $384M invested in Taro Pharmaceutical Industries Ltd. in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 31 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $318M → $384M (+$65.2M)

0% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 31

7% less funds holding

Funds holding: 10194 (-7)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

Holders
94
Holders Change
-7
Holders Change %
-6.93%
% of All Funds
1.85%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
31
Reduced
31
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$63.5M +$122K +1,441 +0.2%
Renaissance Technologies
2
Renaissance Technologies
New York
$54.2M +$2.93M +34,700 +6%
Dimensional Fund Advisors
3
Dimensional Fund Advisors
Texas
$35M +$759K +9,001 +2%
KAM
4
Krensavage Asset Management
New York
$29.9M +$28.7M +339,819 New
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$28.8M -$249K -2,955 -0.9%
Norges Bank
6
Norges Bank
Norway
$16.7M -$884K -10,485 -5%
Invesco
7
Invesco
Georgia
$16.4M +$3.8M +45,002 +32%
APG Asset Management
8
APG Asset Management
Netherlands
$16.1M -$92.8K -1,100 -0.5%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$8.11M +$2.12M +25,118 +37%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$8.04M +$412K +4,882 +6%
OAC
11
OMERS Administration Corp
Ontario, Canada
$7.66M +$3.99M +47,356 +119%
CAM
12
Claret Asset Management
Quebec, Canada
$7.25M -$341K -4,041 -5%
BIP
13
Brandes Investment Partners
California
$7.03M +$2.1M +24,877 +45%
Hotchkis & Wiley Capital Management
14
Hotchkis & Wiley Capital Management
California
$6.7M +$777K +9,210 +14%
Northern Trust
15
Northern Trust
Illinois
$5.4M +$300K +3,561 +6%
Citadel Advisors
16
Citadel Advisors
Florida
$5.09M -$1.29M -15,321 -21%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$5.05M +$761K +9,019 +19%
Arrowstreet Capital
18
Arrowstreet Capital
Massachusetts
$4.79M -$7.03M -83,393 -60%
Millennium Management
19
Millennium Management
New York
$4.38M -$2.75M -32,558 -40%
JP Morgan Chase
20
JP Morgan Chase
New York
$4.27M +$1.81M +21,461 +79%
PPA
21
Parametric Portfolio Associates
Washington
$4.24M -$22.3K -264 -0.5%
Charles Schwab
22
Charles Schwab
California
$3.41M +$130K +1,544 +4%
Wellington Management Group
23
Wellington Management Group
Massachusetts
$3.27M +$56.2K +666 +2%
California Public Employees Retirement System
24
California Public Employees Retirement System
California
$2.9M -$733K -8,685 -21%
AG
25
Algert Global
California
$2.51M +$645K +7,644 +37%

TARO Hedge Fund Activity: Q4 2019 in Review

94 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Taro Pharmaceutical Industries Ltd. (TARO) for Q4 2019, worth a combined $384M — up 20% from $318M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of TARO and 10 opened new positions — a net loss of 7 holders — while 31 trimmed existing stakes and 31 added.

The largest buyer was Krensavage Asset Management, opening a new position worth an estimated $28.7M. The largest seller was Arrowstreet Capital, cutting an estimated $7.03M.

  • 94 institutional investors held Taro Pharmaceutical Industries Ltd. (TARO) as of Q4 2019, down from 101 in Q3 2019.
  • Funds reported $384M of Taro Pharmaceutical Industries Ltd. stock for Q4 2019, up 20% quarter-over-quarter.
  • 10 funds opened new Taro Pharmaceutical Industries Ltd. positions in Q4 2019 and 17 closed out, a net change of -7 holders.
  • The largest Taro Pharmaceutical Industries Ltd. buyer in Q4 2019 was Krensavage Asset Management, an estimated $28.7M added.
  • The largest Taro Pharmaceutical Industries Ltd. seller in Q4 2019 was Arrowstreet Capital, an estimated $7.03M sold.

Based on aggregated 13F filings for Q4 2019.